Differences in Responses to Neoadjuvant Anti-HER2 Therapy between HER2 2+ISH+ and HER2 3+ in HER2-Positive Breast Cancer
Owing to the differences in clinicopathological features and treatment efficacy, we considered the HER2 2+ISH+ group to be a distinct subtype and defined it as the HER2-moderate-positive (HER2-mod) subgroup. In this subgroup, dual anti-HER2 drugs did not exert significant improvement in pCR and DFS. Therefore, treatment optimization is warranted, with ADC drugs as potential options.
Authors
- Lingjun Ma (ORCID: https://orcid.org/0009-0009-2140-4569)
- Xiaoqing Zhang (ORCID: https://orcid.org/0000-0003-3592-293X)
- Xiaoming Zha (ORCID: https://orcid.org/0000-0003-2604-811X)
- Ying Zhu (ORCID: https://orcid.org/0000-0001-9880-5330)
- Jue Wang (ORCID: https://orcid.org/0000-0002-7134-3401)
- Rong Deng (ORCID: https://orcid.org/0000-0002-4165-4436)
- Ran Zheng (ORCID: https://orcid.org/0000-0001-7786-5094)
- Lingyun Xu (ORCID: https://orcid.org/0000-0001-5373-8541)
- Hong Yin (ORCID: https://orcid.org/0000-0002-2973-3801)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Nanjing Traditional Chinese Medicine Hospital (CN)
- Nanjing Maternity and Child Health Care Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Changzhou No.2 People's Hospital (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-04-21
- DOI
- https://doi.org/10.4143/crt.2024.1200
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00